Equities

Dottikon ES Holding AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Dottikon ES Holding AG

Actions
  • Price (CHF)337.00
  • Today's Change1.50 / 0.45%
  • Shares traded2.34k
  • 1 Year change+57.48%
  • Beta1.3507
Data delayed at least 15 minutes, as of Feb 17 2026 16:36 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Dottikon ES Holding AG is a Switzerland-based holding company that specializes in hazardous chemistry and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industries. Its product range includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, as well as industrial chemicals. Its pharmaceutical products can be found in medications for, among others, heart disease, asthma, high blood pressure and ulcers. Dottikon ES Holding AG's industrial end products include food additives, cosmetics, electro-chemicals, photo-chemicals and agricultural chemicals. The Company also offers distillation plants and thin layer evaporators for the recycling of solvents, as well as high temperature incinerators for the waste treatment of hazardous waste. As of March 31, 2012, the Company had two wholly owned subsidiaries: DOTTIKON EXCLUSIVE SYNTHESIS AG and DOTTIKON ES MANAGEMENT AG. It also held a 33.9%-stake in SYSTAG, System Technik AG.

  • Revenue in CHF (TTM)424.30m
  • Net income in CHF120.97m
  • Incorporated2005
  • Employees841.00
  • Location
    Dottikon ES Holding AG5605PO. BoxDOTTIKON 5605SwitzerlandCHE
  • Phone+41 566168201
  • Fax+41 566168945
  • Websitehttps://dottikon.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PTC Therapeutics, Inc.1.37bn578.53m4.29bn939.008.14--7.113.138.538.5321.64-1.950.79321.288.831,894,728.0033.51-26.6849.97-34.8496.8393.4942.25-74.672.266.031.07---13.9721.3242.02---13.92--
Gan & Lee Pharmaceuticals428.59m103.12m4.32bn5.25k41.453.44--10.091.571.576.5418.880.31580.90719.73733,533.107.606.198.106.5874.6281.8024.0622.315.57--0.00144.1216.771.0280.75-12.041.63--
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd8.64bn332.69m4.35bn28.14k13.671.08--0.50331.841.8447.6923.320.95485.794.332,755,662.003.835.337.3610.9516.2318.074.015.281.31--0.287328.87-0.6922.92-30.09-2.32-14.016.32
Laurus Labs Ltd569.84m71.49m4.63bn6.17k64.86--41.728.1315.6115.61124.44--------10,899,350.00--8.88--14.3158.6748.1812.5211.88--7.10--13.7910.1814.42123.187.0223.60--
Beijing Tong Ren Tang Co Ltd2.01bn150.81m4.67bn17.88k31.003.07--2.320.98710.987113.199.960.57360.937611.401,011,323.005.998.1311.7215.9543.1946.0210.4513.341.89--0.162933.284.126.97-8.549.142.305.64
Dottikon ES Holding AG424.30m120.97m4.70bn841.0038.334.4632.1711.078.758.7530.7075.260.31750.65916.12535,050.409.058.0510.529.2567.5772.3728.5125.671.71--0.1111--18.0717.1330.9526.0623.40--
Abbott India Ltd578.53m129.21m4.74bn3.66k36.65--34.948.19717.26717.263,211.47--------18,650,260.00--22.42--30.4246.6144.5922.3318.83--79.05--73.999.589.3817.7518.9927.3134.73
Glenmark Pharmaceuticals Ltd1.40bn90.30m4.86bn13.48k53.82--35.463.4837.7237.72583.32--------12,219,440.00--1.33--1.9271.6860.156.471.82--16.41--39.6212.774.60155.146.18-4.240.00
Rhythm Pharmaceuticals Inc134.17m-152.16m5.04bn283.00--43.94--37.54-3.10-3.102.744.430.40061.036.66616,021.20-44.19-52.46-57.53-61.2289.40---110.32-354.184.53-27.830.2693--68.06---43.26------
Richter Gedeon Vegyeszeti Gyar Nyrt2.18bn548.94m5.23bn11.76k9.361.567.822.401,241.241,241.244,922.297,429.220.57621.333.6976,662,670.0014.5213.5516.2315.3568.6560.7925.2022.342.83--0.015940.476.5111.0550.6138.398.6251.82
Data as of Feb 17 2026. Currency figures normalised to Dottikon ES Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

8.01%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management Switzerland AGas of 31 Mar 2025585.42k4.18%
VV Verm�gensverwaltung AGas of 28 Nov 2025164.31k1.17%
The Vanguard Group, Inc.as of 04 Feb 2026114.88k0.82%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 202588.58k0.63%
Union Bancaire Priv�e, UBP SAas of 30 Sep 202550.83k0.36%
BlackRock Fund Advisorsas of 06 Feb 202634.83k0.25%
Reichmuth & Co.as of 31 Dec 202529.00k0.21%
Norges Bank Investment Managementas of 30 Jun 202524.04k0.17%
Pax Asset Management AGas of 31 Oct 202516.00k0.11%
Baumann & Cie KmGas of 31 Oct 202513.50k0.10%
More ▼
Data from 31 Oct 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.